- • Up to 20% off your first purchase
- • Bulk quantities available
- • Citation Reward application
Sample Application
- Animal health test
- In-vitro diagnostics
- Food & Feed Safety
- Environmental Safety
- New drug discovery
Supports
- Talk to our Expert:
[email protected] -
Talk to our sales:
[email protected]
Protocol Library Download
 |
 |
Anti-CEAM6/ CD66c/ CEACAM6 monoclonal antibody
Anti-CEAM6/ CD66c/ CEACAM6 antibody for FACS & in-vivo assay
Go to CD66c/CEACAM6 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
MSDSProduct information
| Catalog No. | Product Name | Species Reactivity |
|---|---|---|
| GM-Tg-hg-T44513-Ab-1/ GM-Tg-hg-T44513-Ab-2 | Anti-Human CD66c/CEACAM6 monoclonal antibody | Human |
| GM-Tg-rg-T44513-Ab-1/ GM-Tg-rg-T44513-Ab-2 | Anti-Rat CD66c/CEACAM6 monoclonal antibody | Rat |
| GM-Tg-mg-T44513-Ab-1/ GM-Tg-mg-T44513-Ab-2 | Anti-Mouse CD66c/CEACAM6 monoclonal antibody | Mouse |
| GM-Tg-cynog-T44513-Ab-1/ GM-Tg-cynog-T44513-Ab-2 | Anti-Cynomolgus/ Rhesus macaque CD66c/CEACAM6 monoclonal antibody | Cynomolgus/ Rhesus macaque |
| GM-Tg-felg-T44513-Ab-1/ GM-Tg-felg-T44513-Ab-2 | Anti-Feline CD66c/CEACAM6 monoclonal antibody | Feline |
| GM-Tg-cang-T44513-Ab-1/ GM-Tg-cang-T44513-Ab-2 | Anti-Canine CD66c/CEACAM6 monoclonal antibody | Canine |
| GM-Tg-bovg-T44513-Ab-1/ GM-Tg-bovg-T44513-Ab-2 | Anti-Bovine CD66c/CEACAM6 monoclonal antibody | Bovine |
| GM-Tg-equg-T44513-Ab-1/ GM-Tg-equg-T44513-Ab-2 | Anti-Equine CD66c/CEACAM6 monoclonal antibody | Equine |
Size： 1mg | 10mg | 100mg
Product Description
| Catalog No. | GM-Tg-hg-T44513-Ab-1/ GM-Tg-hg-T44513-Ab-2; GM-Tg-rg-T44513-Ab-1/ GM-Tg-rg-T44513-Ab-2; GM-Tg-mg-T44513-Ab-1/ GM-Tg-mg-T44513-Ab-2; GM-Tg-cynog-T44513-Ab-1/ GM-Tg-cynog-T44513-Ab-2; GM-Tg-felg-T44513-Ab-1/ GM-Tg-felg-T44513-Ab-2; GM-Tg-cang-T44513-Ab-1/ GM-Tg-cang-T44513-Ab-2; GM-Tg-bovg-T44513-Ab-1/ GM-Tg-bovg-T44513-Ab-2; GM-Tg-equg-T44513-Ab-1/ GM-Tg-equg-T44513-Ab-2 |
| Products Name | Anti-CD66c/CEACAM6 monoclonal antibody |
| Format | mab |
| Target Name | CD66c |
| Protein Sub-location | Transmembrane Protein |
| Category of antibody | FACS/Biofunctional Antibody, Therapeutics Target antibody |
| Derivation (species) | Mouse |
| CH1+2+3 Isotype (Receptor identification) | IgG |
| Type of Light Chain (VD-LC) | N/A |
| Expression platform | Mammalian Expression |
| Bioactivity validation | Binding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD). |
| Tag | Fc |
| Products description | Pre-made anti-CD66c benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
| Purity | Purity: ≥95% (SDS-PAGE) |
| Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
| Formulation | Lyophilized from sterile PBS, PH 7.4 |
| Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
| Category | Cat No. | Products Name |
| Biosimilar | GMP-Bios-ab-578 | Pre-Made Tinurilimab biosimilar, Whole mAb, Anti-CEACAM6/CD66c Antibody: Anti-CEAL/NCA therapeutic antibody |
| Biosimilar | GMP-Bios-INN-886 | Pre-Made Lemalesomab Biosimilar, Whole Mab: Anti-Nca-90 (Nonspecific Cross- Reacting Antigens 90Kda Glycoproteins, Granulocyte Cell Antigen) [human] therapeutic antibody |
| Target Antigen | Products Developing | Multi-species CEAM6/ CD66c/ CEACAM6 VLP (virus-like particle) (Products Developing) |
| ORF Viral Vector | vGMLP001615 | human CEACAM6 Lentivirus particle |
| ORF Viral Vector | pGMLP001615 | human CEACAM6 Lentivirus plasmid |
Target information
| Target ID | GM-T44513 |
| Target Name | CD66c |
| Gene ID | 4680,106994775 |
| Gene Symbol and Synonyms | CD66c,CEACAM6,CEAL,NCA |
| Uniprot Accession | P40199 |
| Uniprot Entry Name | CEAM6_HUMAN |
| Protein Sub-location | Transmembrane Protein |
| Category | Therapeutics Target, INN Index |
| Disease | Cancer |
| Gene Ensembl | ENSG00000086548 |
| Target Classification | Tumor-associated antigen (TAA) |
The target: CD66c, gene name: CEACAM6, also named as CD66c, CEAL, NCA. This gene encodes a protein that belongs to the carcinoembryonic antigen (CEA) family whose members are glycosyl phosphatidyl inositol (GPI) anchored cell surface glycoproteins. Members of this family play a role in cell adhesion and are widely used as tumor markers in serum immunoassay determinations of carcinoma. This gene affects the sensitivity of tumor cells to adenovirus infection. The protein encoded by this gene acts as a receptor for adherent-invasive E. coli adhesion to the surface of ileal epithelial cells in patients with Crohn's disease. This gene is clustered with genes and pseudogenes of the cell adhesion molecules subgroup of the CEA family on chromosome 19. [provided by RefSeq, Apr 2014].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.
Facebook
LinkedIn
Twitter
